Overview

Granulocyte Macrophage-Colony Stimulating Factor (GM-CSF) Inhalation to Improve Host Defense and Pulmonary Barrier Restoration

Status:
Active, not recruiting

Trial end date:
2022-07-31

Target enrollment:

Participant gender:

Summary

This trial evaluates efficacy and safety of inhaled molgramostim (rhGM-CSF) in 45 patients with pneumonia associated acute respiratory distress syndrome (ARDS). A third of the patients will receive 150 mcg inhaled molgramostim, another third 450 mcg and the remaining third will receive inhaled placebo for 3 days. The patients will be followed for 28 days.

Phase:

Phase 2

Details

Lead Sponsor:

Savara Inc.
University of Giessen

Treatments:

Molgramostim
Sargramostim